EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Radiopharm Theranostics Ltd (RAD) fair value: what the stock is really worth

We calculate from audited financials what Radiopharm Theranostics Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 16, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · AU · ISIN AU0000181851

RT Radiopharm Theranostics Ltd logo Thin data Jul 16, 2026

Radiopharm Theranostics Ltd

RAD · AU

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value A$0.0147 · Strongly undervalued (+110%)
!Quality 46/100
!Mixed Growth (revenue 3y +1049.1 %/yr)
!negative free cash flow
✓Ranks above peers (5/7)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Radiopharm Theranostics Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.3652 A$0.0070 Fair Value A$0.0147 Nov 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.

How to read this chart

58‑month range A$0.0070 – A$0.3652 · fair‑value band A$0.0147 – A$0.0163 · the A$0.0070 price screens below the A$0.0147 fair value. Dashed = 300-day average. As of Jul 16, 2026.

Follow Radiopharm Theranostics in your weekly email

Every Wednesday you see whether Radiopharm Theranostics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

Show more

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Stock analysis

Radiopharm Theranostics Ltd (RAD) currently trades at A$0.0070, while our model-based Fair Value estimate is A$0.0147, implying the stock looks roughly 52.4% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: A$0.0147 (bear) to A$0.0163 (bull), the price of A$0.0070 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Radiopharm Theranostics Ltd reported revenue of A$13.4M in FY2025 versus A$0 in FY2021. Reported net income was −A$36.7M in FY2025.

Key figures

Market cap A$44.9M (≈ $31.6M) · P/S ratio 2.76 · EPS (TTM) A$−0.0200 · Net margin −286% · Return on equity −92.1% · Return on assets (EBIT) −327% · Operating margin −424% · Revenue (TTM) A$16.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 81% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 110%, RAD screens cheaper than that median.

Fair Value models

Bear A$0.0147 Fair Value A$0.0147 Bull A$0.0163
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) A$0.0100 A$0.0100 A$0.0200 50
All 1 models by family
Asset-Based
NCAV (Graham) A$0.0100 A$0.0100 A$0.0200 50

Open the full fair value analysis →

Notify me when RAD reaches fair value

Put RAD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 46 · Market factors (momentum, volatility) 11

Profitability 4
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 69
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 39
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4,378.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1,049.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−225,527.7% (2022) → −284.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch RAD, get fair value alerts →

Compare Radiopharm Theranostics Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 4/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside +110% · Top 25%
Profitability
Return on assets −28% · Below median
Growth and dividend
Revenue growth 155% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.71× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 1.94× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Radiopharm Theranostics Ltd · Fair Value
A$0.0147 +52%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Radiopharm Theranostics Ltd Fair Value". https://www.fairvalue-calculator.com/stock/RAD

Frequently asked questions

Is Radiopharm Theranostics Ltd (RAD) overvalued or undervalued?
As of Jul 16, 2026, our model estimates a fair value of A$0.0147 versus a price of A$0.0070, about +110% upside (undervalued).
What is the fair value of RAD?
Our model-based fair value for Radiopharm Theranostics Ltd is A$0.0147 (as of Jul 16, 2026), built from audited fundamentals. The current price: A$0.0070.
What is the quality score of RAD?
Radiopharm Theranostics Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Radiopharm Theranostics Ltd (RAD)?
Our model-based price target is the fair value of A$0.0147 (as of Jul 16, 2026) from 1 valuation models. Cautious scenario A$0.0147, optimistic scenario A$0.0163. It is a calculation from audited fundamentals, not an analyst target.
What is the Radiopharm Theranostics Ltd stock forecast for 2026?
Our models put fair value at A$0.0147, about +110% upside versus a price of A$0.0070 (undervalued). Cautious scenario A$0.0147, optimistic scenario A$0.0163. The calculation is refreshed regularly with new filings.
What is the revenue of Radiopharm Theranostics Ltd (RAD)?
Radiopharm Theranostics Ltd reported trailing-twelve-month revenue of about A$16.3M (latest available figure, as of Jul 16, 2026).
What is the intrinsic value of Radiopharm Theranostics Ltd (RAD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Radiopharm Theranostics Ltd it is A$0.0147 per share (as of Jul 16, 2026), against a price of A$0.0070. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Radiopharm Theranostics Ltd stock overvalued or undervalued in 2026?
As of Jul 16, 2026, RAD trades below its calculated fair value: price A$0.0070, fair value A$0.0147, a gap of about +110% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RAD?
No. The price is what the market pays today (A$0.0070); the fair value is what the company's own numbers justify (A$0.0147). For Radiopharm Theranostics Ltd the two are A$0.0077 per share apart. That gap is exactly why we show both numbers side by side.
How much is Radiopharm Theranostics Ltd worth?
The market values Radiopharm Theranostics Ltd at about A$44.9M (market capitalisation, as of Jul 16, 2026). Per share that is A$0.0070; our models calculate a fair value of A$0.0147 per share.
What do the bullish and bearish scenarios say about RAD?
Our models span a range for Radiopharm Theranostics Ltd: cautious scenario A$0.0147, base A$0.0147, optimistic A$0.0163 per share (as of Jul 16, 2026, price A$0.0070). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Radiopharm Theranostics Ltd (RAD)?
Balance-sheet figures for Radiopharm Theranostics Ltd (as of Jul 16, 2026): return on equity −92.1%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is RAD from its 52-week high?
Radiopharm Theranostics Ltd trades at A$0.0070, about 81% below its 52-week high of A$0.0370 and at the low of A$0.0070 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0147 is for.
Which stocks are comparable to Radiopharm Theranostics Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Radiopharm Theranostics Ltd stock attractive at the current price?
The data as of Jul 16, 2026: price A$0.0070, calculated fair value A$0.0147 (+110%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RAD calculated?
We run Radiopharm Theranostics Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0147, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Radiopharm Theranostics Ltd currently trades 110 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Radiopharm Theranostics Ltd (RAD)?
The closing price on Sep 24, 2026 was A$0.0070. Our model-based fair value is A$0.0147, about +110% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Radiopharm Theranostics Ltd right now?
The price is below even our cautious bear case (A$0.0147). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality. The models converge in a tight band (A$0.0147 to A$0.0163), unusually little disagreement for a valuation.

Key figures of Radiopharm Theranostics Ltd

How large is the market capitalisation of Radiopharm Theranostics Ltd (RAD)?
The market capitalisation of Radiopharm Theranostics Ltd is A$44.9M (≈ $31.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Radiopharm Theranostics Ltd (RAD)?
The price-to-sales ratio of Radiopharm Theranostics Ltd is 2.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Radiopharm Theranostics Ltd (RAD)?
Earnings per share at Radiopharm Theranostics Ltd are A$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Radiopharm Theranostics Ltd (RAD)?
The net margin of Radiopharm Theranostics Ltd is −286% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Radiopharm Theranostics Ltd (RAD)?
The return on equity (ROE) of Radiopharm Theranostics Ltd is −92.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Radiopharm Theranostics Ltd (RAD)?
On an EBIT basis the return on assets of Radiopharm Theranostics Ltd is −327% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Radiopharm Theranostics Ltd (RAD)?
The operating margin of Radiopharm Theranostics Ltd is −424% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Radiopharm Theranostics Ltd (RAD)?
Revenue at Radiopharm Theranostics Ltd is growing +155% versus a year earlier (3y avg +1,049%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Radiopharm Theranostics Ltd (RAD) generate?
The free cash flow of Radiopharm Theranostics Ltd is −A$36.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Radiopharm Theranostics Ltd (RAD) hold?
Radiopharm Theranostics Ltd holds more cash than debt, A$29.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Radiopharm Theranostics Ltd in the live analysis

One click puts Radiopharm Theranostics Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.